JamesWFrestonMDPhD, FAGA

PubMed

• 7 citations
  Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical ...
  David H Alpers, James H Lewis, Christine M Hunt, James W Freston, Vicente E Torres, Hui Li, Wenchyi Wang, Molly E Hoke, Sharin E Roth, Lucas Westcott-Baker, Alvin Estilo> ;American Journal of Kidney Diseases. 2023 Mar 1
• 11 citations
  Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
  Daniel C. Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H. Taylor, Ayako Suzuki, James H. Lewis, James W. Freston, Stephan Lanes> ;BMC Cancer. 2021 Jan 25
• 16 citations
  Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chroni...
  William R. Treem, Melissa Palmer, I. Lonjon-Domanec, Daniel Seekins, Lara Dimick-Santos, Mark I. Avigan, John Marcinak, Ajit Dash, Arie Regev, E Maller, Meenal Patward...> ;Drug Safety. 2021 Feb 1
• 27 citations
  Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
  Arie Regev, Mark I. Avigan, Alexandre Kiazand, John M. Vierling, James H. Lewis, Stephanie O. Omokaro, Adrian M. Di Bisceglie, Robert J. Fontana, Herbert L. Bonkovsky,...> ;Journal of Autoimmunity. 2020 Nov 1
• 24 citations
  Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with non...
  Arie Regev, Melissa Palmer, Mark I. Avigan, Lara Dimick-Santos, William R. Treem, John Marcinak, Daniel Seekins, Gopal Krishna, Frank A. Anania, James W. Freston, Jame...> ;Alimentary Pharmacology & Therapeutics. 2019 Feb 13
• 24 citations
  Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
  George B. McDonald, James W. Freston, James L. Boyer, Laurie D. DeLeve> ;Hepatology. 2019 Feb 1
• Presentation of the Julius M. Friedenwald Medal to David A. Peura, MD, AGAF.
  James W. Freston, Cynthia Yoshida> ;Gastroenterology. 2011 Jun 1
• 84 citations
  Clinical and histopathologic features of fluoroquinolone-induced liver injury.
  Eric S. Orman, Hari S. Conjeevaram, Raj Vuppalanchi, James W. Freston, James Rochon, David E. Kleiner, Paul H. Hayashi> ;Clinical Gastroenterology and Hepatology. 2011 Jun 1
• 9 citations
  Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
  Marian M. Haber, Barbara Hunt, James W. Freston, David A. Peura, Thomas O. Kovacs, Stuart Atkinson, M. Hisada> ;Alimentary Pharmacology & Therapeutics. 2010 Jul 1
• 237 citations
  Causality assessment in drug‐induced liver injury using a structured expert opinion process: Comparison to the Roussel‐Uclaf causality assessment method
  Don C. Rockey, Leonard B. Seeff, James Rochon, James W. Freston, Naga Chalasani, Maurizio Bonacini, Robert J. Fontana, Paul H. Hayashi> ;Hepatology. 2010 Jun 1
• 112 citations
  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
  Ayako Suzuki, Raúl J. Andrade, Einar Bjornsson, M. Isabel Lucena, William M. Lee, Nancy A. Yuen, Christine M. Hunt, James W. Freston> ;Drug Safety. 2010 Jun 1
• 5 citations
  Long-Term Quality of Life Improvement in Subjects with Healed Erosive Esophagitis: Treatment with Lansoprazole
  Thomas O. Kovacs, James W. Freston, Marian M. Haber, Stuart Atkinson, Barbara Hunt, David A. Peura> ;Digestive Diseases and Sciences. 2010 May 1
• 7 citations
  Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis.
  Thomas O. Kovacs, James W. Freston, Marian M. Haber, Barbara Hunt, Stuart Atkinson, David A. Peura> ;Digestive Diseases and Sciences. 2009 Mar 7
• 16 citations
  The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis
  James W. Freston, M. Hisada, David A. Peura, Marian M. Haber, Thomas O. Kovacs, Stuart Atkinson, Barbara Hunt> ;Alimentary Pharmacology & Therapeutics. 2009 Jun 1
• 4 citations
  Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine
  David A. Peura, James W. Freston, Marian M. Haber, Thomas O. Kovacs, Barbara Hunt, Stuart Atkinson> ;Digestive Diseases and Sciences. 2009 May 1
• 40 citations
  Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone: Results from a 3-Year, Randomized, Comparator-Controlled Study in the US
  Keith G. Tolman, James W. Freston, Stuart Kupfer, Alfonso Perez> ;Drug Safety. 2009 Jan 1
• 16 citations
  Use of pH-impedance testing to evaluate patients with suspected extraesophageal manifestations of gastroesophageal reflux disease.
  Ashish Malhotra, James W. Freston, Khalid Aziz> ;Journal of Clinical Gastroenterology. 2008 Mar 1
• 1 citations
  Recurrent pneumonia from severe nonacid reflux: a case report and discussion.
  Ashish Malhotra, James W. Freston, Maria Soriano, Khalid Aziz> ;Connecticut Medicine. 2007 Aug 1
• 18 citations
  Proton Pump Inhibitors: Effective First-Line Treatment for Management of Dyspepsia
  David A. Peura, Jeff Gudmundson, Nancy Y. Siepman, Betsy L. Pilmer, James W. Freston> ;Digestive Diseases and Sciences. 2007 Mar 7
• 7 citations
  Advancing patient care: integrating new data.
  Teresa L. Wright, Canan Avunduk, Jules L. Dienstag, James W. Freston, Ira M. Jacobson, H Juergen Nord, Morris Sherman> ;The American Journal of Gastroenterology. 2006 Feb 1
• 3 citations
  Rating the severity of the medical consequences of drug-induced liver injury.
  D.E. Slavin, C.L. Schlichting, James W. Freston> ;Regulatory Toxicology and Pharmacology. 2005 Nov 1
• 1 citations
  Our new president-David a. Peura, MD.
  James W. Freston, Cynthia Yoshida> ;Gastroenterology. 2005 May 1
• 8 citations
  Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
  James W. Freston> ;The American Journal of Medicine. 2004 Sep 6
• 11 citations
  A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
  J. W. Freston, Michael J. Kukulka, E. Lloyd, C. Q. Lee> ;Alimentary Pharmacology & Therapeutics. 2004 Aug 1
• 27 citations
  Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
  J. W. Freston, Betsy L. Pilmer, Y.-L. Chiu, Q. Wang, J. C. Stolle, J. S. Griffin, C. Q. Lee> ;Alimentary Pharmacology & Therapeutics. 2004 May 1
• Join now to see all

Journal Articles

• Liver Complications Following Treatment of Hematologic Malignancy with Anti‐cd22‐Calicheamicin (Inotuzumab Ozogamicin)  
  James W Freston, Laurie D DeLeve, George B McDonald, Hepatology
• Clinical and histological features of fluoroquinolone-induced liver injury  
  Eric S. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rachon J, Kleiner DE, Hayashi PH, Clinical Gastroenterology and Hepatology, 1/1/2011
• A Causality assessment in drug-induced liver disease using a structured expert opinion process: Comparison to the Roussel Unclaf causality assessment method  
  Rockey DC, Seeff, LB, Rochon J, Freston J. Chalasani N, Bonacine M, Fontana RR, Hayashi P, Hepatology, 1/1/2010
• Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBaseTM: Unified list based on International collaborative work  
  Suzuki A, Andrade RJ , Bjornsson E, Lucena IM, Lee W, Yuen N, Hunt CN, Watkins P, Freston JW, Drug Safety, 1/1/2010
• Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy  
  Haber M, Hunt B, Freston JW, Peura DA, Kovacs TO, Atkinson S, Hisada M, Alimentary Pharmacology & Therapeutics, 1/1/2010
• The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis  
  Freston JW, Hisada M, Peura DA, Haber MM, Kovacs TO, Atkinson S, Hunt B, Aliment Pharmacol Therap, 1/1/2009
• Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study  
  Tolman K, Freston JW, Kupfer S, Perez A, Drug Safety, 1/1/2009
• Use of pH-Impedance Testing to Evaluate Patients With Suspected Extraesophageal Manifestations of Gastroesophageal Reflux Disease  
  Malhotra A, Freston JW, Aziz K, J.Clin.Gastroenter., 1/1/2008
• Vector analysis to detect hepatotoxicity signals in drug development  
  Trost CD, Freston JW, Drug Information Journal, 1/1/2008
• Colorectal cancer screening: a retrospective study of compliance with guidelines in a university-based primary care practice  
  Mulhotra A, Freston JW, Soriano M, Aziz K, Quality in Primary Care, 1/1/2007
• Recurrent Pneumonia from severe nonacid reflux: a case report and discussion  
  Mulhotra A, Freston JW, Soriano M, Aziz K, Connecticut Medicine, 1/1/2007
• Advancing Patient Care for Chronic Hepatitis B  
  Wright TL, Avunduk C, Dienstag JL, Freston JW, Jacobson IM, Nord HJ, Sherman M, Am J Gastroenterol, 1/1/2006
• Our new president – David A Peura, MD  
  Freston JW, Yoshida CM, Gastroenterol, 1/1/2005
• Rating the severity of the medical consequences of drug-induced liver injury  
  Slavin DE, Schlichtine CL, Freston JW, Regulatory Toxicology and Pharmacology, 1/1/2005
• Approaches to the long-term management of adults with GERD: proton pump inhibitor therapy, laparascopic fundoplication or endoscopic therapy?  
  Freston JW, Triadofilopoulas G, Aliment Pharmacol Ther, 1/1/2004
• Management of GERD in children and Adults  
  Gold B, Freston JW, Pediatric Gastroenterology, 1/1/2003
• Comparative pharmacokinetics and safety of lansoprazole oral capsules and fast-disintegrating tablets in healthy subjects  
  Freston JW, Chiu YL, Mulford DJ, Ballard II ED, Aliment Pharmacol Ther, 1/1/2003
• Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis and role of proton pump inhibitors in treatment  
  Gold BD, Freston JW, Pediatr Drug, 1/1/2002
• Differences among the PPIs  
  Howden CW (editor), Freston JW, SCOPE, 1/1/2002
• Motion – All patients with GERD should be offered once-in-a-lifetime endoscopy: Arguments against the motion  
  Freston JW, Can J Gastroenterol, 1/1/2002
• Looking for Hepatotoxicity, Working up Patients, and Assessing Causality  
  Freston JW, 2/12/2001
• Attributable risk of H, pylori in peptic ulcer disease Does declining prevalence of infection in general population explain increasing frequency of non-H pylori ulcers?  
  Sugiyama T, Nishikawa K, Komatsu Y, Ishizuka J, Mizushima T, Kumagai A, Kato M, Saito N, Takeda H, Asaka M, Freston JW, Dig Dis Sci, 1/1/2001
• Should we eradicate H pylori before long-term anti-reflux therapy?  
  Freston JW, Gut, 1/1/2001
• Review article: Role of proton pump inhibitors in non-H pylori-related ulcers  
  Freston JW, Aliment Pharmacol Therap, 1/1/2001
• The evolving roles of proton pump inhibitors in long-term care of acid related disorders  
  Freston JW, Garnett W, Annals of Long-Term Care, 1/1/2001
• Join now to see all

Books/Book Chapters

• UpToDate, Revised 
  Chapter: H. pylori-negative ulcer disease. 
  Varadarajulu S, Freston JWEditors: Rose BD.UpToDate, Wellesley, MA2005
• Focus on GERD and NSAID-related ulcers. 
  Chapter: Patient with recurrent nocturnal heartburn. 
  Page 19 - 25Freston JWEditors: Howden CW, and Peura DA.McMahon Publishing Group, New York2004
• Helicobacter pylori and gastritis – Basic mechanisms to clinical cure 2002. 
  Chapter: Helicobacter pylori eradication is not necessary before long-term proton pump inhibitor treatment. Helicobacter pylori 
  Page 311 - 317Freston JWEditors: Hunt RH, Tytgat GNJ.Kluwer Academic Publishers, Norwell, MA2002
• UpToDate 
  Chapter: H. pylori-negative ulcer disease. 
  Varadarajulu S, Freston JWEditors: Rose BD.UpToDate, Wellesley, MA2002
• Diseases of the gastroesophageal mucosa: The acid-related disorders. 
  Page 1 - 199Editors: Freston JW.Humana Press Inc., Totowa, NJ2001
• Diseases of the gastroesophageal mucosa: The acid related disorders. 
  Chapter: Peptic ulcer disease: Overview and management. 
  Page 3 - 27Varadarajulu S, Freston JWEditors: Freston JW.Humana Press Inc., Totowa, NJ2001
• Diseases of the gastroesophageal mucosa: The acid related disorders. 
  Chapter: Gastroesophageal reflux disease: Diagnosis and treatment. 
  Page 137 - 166Cymorek, JH, Freston, JWEditors: Freston JW.Humana Press Inc., Totowa, NJ2001
• CME series for primary care physicians. Part 1 
  Chapter: Medical Simulations. Management of Acid-Related Disorders. 
  Varadarajulu SS, Freston JWAlbert Einstein College of Medicine2000
• Helicobacter pylori: In: Helicobacter pylori and gastritis – Basic mechanisms to clinical cure 2000. 
  Chapter: Proton pump inhibitors do not accelerate the development of gastric atrophy in Helicobacter pylori gastritis. 
  Page 269 - 280Freston JWEditors: Hunt RH, Tytgat GNJ.Kluwer Academic Publishers, Norwell, MA2000
• Helicobacter pylori - Basic mechanisms to clinical cure 1998. 
  Chapter: Helicobacter pylori: The clinical agenda. 
  Page 490 - 498Freston JWEditors: Hunt RH, Tytgat GNJ.Kluwer Academic Publishers, Norwell, MA1998
• The Toxicology Forum - Given Institute, Aspen, CO 
  Chapter: Mechanisms of induction and toxicological significance of gastric carcinoids: Relevance of rodent tumors to humans. 
  Page 729 - 736Freston JWThe Toxicology Forum, Inc., Washington, DC1998
• Digestive Diseases Self-Education Program (DDSEP) A core curriculum and self-assessment in gastroenterology and hepatology. 
  Editors: Freston JW.Kendall/Hunt Publishing Co., Dubuque, IA1998
• The 83rd General Meeting of Japanese Society of Gastroenterology - Future Trends in Gastroenterology. 
  Chapter: Overviews of controversies in acid-related diseases: Implication for the future. 
  Page 5 - 16Freston JWEditors: Nakazawa S.Life Science Publishing, Tokyo1998
• Gastrointestinal pharmacology and therapeutics. 
  Chapter: Acid-related disease. 
  Page 21 - 78Freston JWEditors: Jacobson ED, Friedman G, McCallum RW.Lippincott Raven Publishers1997
• Gastrointestinal pharmacology and therapeutics. 
  Chapter: Helicobacter pylori induced gastric and ulceration: Epidemiology, pathophysiology and therapeutics. 
  Page 21 - 29Malfertheiner P, Freston JWEditors: Jacobson ED.Lippincott Raven Publishers1997
• Helicobacter pylori: Basic mechanisms to clinical cure 1996. 
  Chapter: Helicobacter pylori, acid, gastritis, atrophy and progression to cancer: A critical view. 
  Page 245 - 254Freston JWEditors: Hunt R, Tytgat GNJ.Kluwer Academic Publishers1996
• Critical issues in the era of proton pump inhibitors: Point and counterpoint. 
  Freston JW1995
• Do PPI effects on the cytochrome P450 system have implications to significant drug interactions? The Esophageal Mucosa. 
  Chapter: PPI effects on the cytochrome P450 system. 
  Page 460 - 464Rodrigues AD, Freston JWEditors: Giuli R, Tytgat G, Dameester T, Galmisch JP.Elsevier, Amsterdam1994
• Proton pump inhibitors and acid-related disorders. 
  Chapter: The medical treatment of acute peptic ulcer disease. 
  Page 101 - 117Freston JW, Porro GBEditors: Hunt R.Adis International Limited, Osaka1994
• Proton pump inhibitors and acid-related disorders. 
  Chapter: The long-term management of peptic ulcer disease: Analysis of approaches and recommendations. 
  Page 121 - 136Porro GB, Freston JW, Lazzaroni MEditors: Hunt R.Adis International Limited, Osaka1994
• Atlas of gastroenterology. 
  Chapter: Chapter 47: Approach to gastrointestinal problems associated with common clinical conditions. 
  Page 92 - 97Freston JW, Moore JREditors: Yamada T.JB Lippincott, Philadelphia1992
• Textbook of gastroenterology. 
  Chapter: Chapter 47: Approach to gastrointestinal problems associated with common clinical conditions. 
  Page 928 - 942Freston JW, Moore JREditors: Yamada T.JB Lippincott, Philadelphia1991
• Practical approaches to the management of dyspepsia. 
  Chapter: The patient's perspective of dyspepsia. 
  Page 7 - 10Freston JWEditors: Colin-Jones DG.The Medicine Group, Langhorne1989
• Concepts and controversies in gastroenterology. 
  Page 1 - 48Editors: Freston JW, Pounder R.Norwegian University Press, Norway1987
• Postgraduate medicine: Custom communications, Cimetidine '85 new insights from a decade of continuing research. 
  Editors: Freston JW, Isenberg JI.McGraw-Hill, New York1985
• Join now to see all

Other

• Use and limitations of the RUCAM in hepatotoxicity adjudication. 
  Freston JW
  1/1/2006
• Method for predicting the onset or change of a medical condition. 
  DC Trost, JW Freston, J Ostroff, US Patent App. 10/968,675, 2004 - Google Patents US 20050119534A1 (19) United States (12) Patent Ap
  6/2/2005
• Digestive Diseases Self-Education Program. A core curriculum and self assessment in gastroenterology and hepatology. CD-ROM, syllabus, atlas, and exam. 
  Freston JW, A CME Program, American Gastroenterological Association
  1/1/1998
• Point and Counterpoint: Issues and Answers in Digestive Disease 
  Freston JW, CD-ROM CME Accredited Program
  1/1/1997
• Peptic Ulcer Disease (Video) 
  Freston JW, Time-Life Books
  1/1/1996
• The AGA: Second Century of Excellence (Video) 
  Freston JW
  1/1/1996
• Highlights of The World Congress of Gastroenterology -Australia, Audiotape for General Physician 
  Freston JW
  1/1/1990
• Highlights of The World Congress of Gastroenterology - Brazil, i. Audiotape for General Physician 
  Freston JW
  1/1/1986
• Management of Acute Abdominal Pain - Computerized Interactive Laser Disc 
  Freston JW, i. WICAT, New York
  1/1/1985
• Approach to Peptic Ulcers - Computerized Interactive Laser Disc 
  Freston JW, i. WICAT, New York
  1/1/1984
• Management of Upper Gastrointestinal Bleeding - Computerized Interactive Laser Disc 
  Freston JW, i. WICAT, New York
  1/1/1983
• Highlights of The World Congress of Gastroenterology - Sweden, Audiotape for General Physician 
  Freston JW
  1/1/1982
• Experimental cholelithiasis. Ph.D. Thesis 
  Freston JW, (Medicine) University of London
  1/1/1967
• Join now to see all